LTG-2950

N/A

Report date: 2025/01/26 18:31:12

Base Information

Drug NameLTG-2950
Drug Alias Nametri-specific anti-CD19/anti-CD20/anti-CD22 CAR T-cell therapy (Lentigen/University of Maryland)LTG-2950
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionCD22 modulatorsB-lymphocyte antigen CD20 modulatorsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD20CD22B-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity of Maryland School of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Maryland School of MedicineLentigen Technology Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A